Mineralys Therapeutics, Inc.
MLYS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MLYS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MLYS
Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor, for hypertension and chronic kidney disease, with a PDUFA date in December 2026.
Key risk: Single-product dependency
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 3 clinical trials · 2 catalysts for Mineralys Therapeutics, Inc..
Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor, for hypertension and chronic kidney disease, with a PDUFA date in December 2026.
- Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor, for hypertension and chronic kidney disease [sec].
- As of June 30, 2026, the company reported cash, cash equivalents, and investments of $661.4 million [sec_mda · as of 2026-08-11].
- The company submitted a New Drug Application (NDA) to the FDA for lorundrostat for the treatment of hypertension in December 2025 [sec_mda · as of 2026-05-06].
- As of March 31, 2026, the company had an accumulated deficit of $496.5 million [sec_mda · as of 2026-05-06].
- The company's future performance is dependent entirely on the success of lorundrostat [sec · filed 2024-10-30].
What works
- Lorundrostat has demonstrated clinically meaningful reductions in systolic blood pressure and a favorable safety profile in Phase 2 trials [sec_mda · as of 2025-08-12].
- The company has a strong cash position of $661.4 million as of June 30, 2026, which may support ongoing development and potential commercialization [sec_mda · as of 2026-08-11].
- The NDA submission for lorundrostat in hypertension has been accepted by the FDA, with a PDUFA date of December 22, 2026, indicating progress toward potential approval [sec_mda · as of 2026-05-06].
What to weigh
- The company's future performance is entirely dependent on the success of lorundrostat, creating significant single-product risk [sec · filed 2024-10-30].
- As of March 31, 2026, the company had an accumulated deficit of $496.5 million, reflecting substantial historical losses [sec_mda · as of 2026-05-06].
- Clinical trials are costly and uncertain, and the company may deplete its capital resources sooner than expected [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
The company's future performance is entirely dependent on the success of lorundrostat.
“the Company's future performance is dependent entirely on the success of lorundrostat”
SEC filings · October 30, 2024
As of June 30, 2026, the company had $661.4 million in cash, cash equivalents, and investments.
“As of June 30, 2026, we had cash, cash equivalents, and investments of $661.4 million.”
SEC MD&A · August 11, 2026
The company submitted an NDA for lorundrostat for hypertension in December 2025.
“our new drug application (NDA) that was submitted to the FDA for lorundrostat for the treatment of hypertension when used in combination with other antihypertensive drugs in December 2025”
SEC MD&A · May 6, 2026
As of March 31, 2026, the company had an accumulated deficit of $496.5 million.
“As of March 31, 2026, we had cash, cash equivalents, and investments of $646.1 million and an accumulated deficit of $496.5 million.”
SEC MD&A · May 6, 2026
Catalyst timeline
- 2026-12-22 · PDUFA · lorundrostat — The FDA decision on the NDA for lorundrostat for hypertension is expected on this date.
- 2027-05-01 · Phase3_Topline — Topline results from the open-label extension study assessing long-term safety, efficacy, and tolerability of lorundrostat are expected.
Risks & what to watch (3)›
Key risks
- Single-product dependency — The company's future performance is entirely dependent on the success of lorundrostat [sec · filed 2024-10-30].
- Significant accumulated deficit — As of March 31, 2026, the company had an accumulated deficit of $496.5 million [sec_mda · as of 2026-05-06].
- Clinical trial uncertainty — Clinical trials are costly and uncertain, and the company may deplete capital resources sooner than expected [sec_mda · as of 2026-08-11].
What to watch
- PDUFA date for lorundrostat on December 22, 2026, which will determine FDA approval for hypertension [upcoming catalysts].
- Topline results from the Phase 3 open-label extension study of lorundrostat expected around May 1, 2027 [upcoming catalysts].
- Topline results from the Explore-OSA trial in participants with obstructive sleep apnea and uncontrolled hypertension, anticipated in the first half of 2026 [sec_mda · as of 2025-08-12].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Mineralys Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Mineralys Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
27.3 months
D/E 0.21 · 0% dilution
Lead: Phase 3
1 candidate
2 upcoming, next in ~114d
2 buys · 34 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
215
Total value held
$2.46B
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 7,692,750 | $208.4M |
| samsara biocapital, llc | 5,871,018 | $159.0M |
| vanguard capital management llc | 4,908,726 | $133.0M |
| fmr llc | 4,861,104 | $131.7M |
| blackrock, inc. | 4,481,582 | $121.4M |
| wellington management group llp | 3,359,068 | $91.0M |
| caption management, llc | 3,273,400 | $88.7M |
| state street corp | 2,935,940 | $79.5M |
| caligan partners lp | 2,772,654 | $75.1M |
| laurion capital management lp | 2,232,040 | $60.5M |
Showing top 10 of 215 institutional holders of Mineralys Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 7, 2026- % of float
- 12.9%
- Days to cover
- 6.2
- Shares short
- 8,778,401
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MLYS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Mineralys Therapeutics, Inc.?
Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor, for hypertension and chronic kidney disease, with a PDUFA date in December 2026.
What is Mineralys Therapeutics, Inc.'s lead drug candidate?
Mineralys Therapeutics, Inc.'s most advanced tracked candidate is lorundrostat (Phase 3) for Obstructive Sleep Apnea; Hypertension.
What is Mineralys Therapeutics, Inc.'s next catalyst?
Mineralys Therapeutics, Inc.'s next tracked catalyst is a PDUFA event — "PDUFA Date: lorundrostat" — expected December 22, 2026.
Who is the CEO of Mineralys Therapeutics, Inc.?
Dr. Jon Congleton is the chief executive officer of Mineralys Therapeutics, Inc. (MLYS).
Where is Mineralys Therapeutics, Inc. headquartered?
Mineralys Therapeutics, Inc. (MLYS) is headquartered in Radnor, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.